Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel

Source Summary

SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) or certain of its officers and directors violated federal securities laws by misrepresenting or failing to timely disclose material information to investors.